Lutris Pharma

Location: Israel, office address not availableBiotechB2Blutris-pharma.com

Lutris Pharma develops LUT014, a topical gel in Phase 2 for rash and skin side effects of EGFR inhibitor cancer treatments such as cetuximab.

Founders and contacts

FoundersBeing confirmed, locked
Founder emailsBeing confirmed, locked

See Israel on the map

More startups in Israel

Are you a founder of Lutris Pharma and want your details removed? Write to us and we remove them within 72 hours.